Bimatoprost in the Treatment of Eyelash Hypotrichosis

Study Identifier
192024-046
CT.gov Identifier
NCT01698554
EudraCT Identifier
2012-003007-35
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Hypotrichosis
    • Study Drug
  • bimatoprost formulation A solution
  • bimatoprost solution 0.03 %
  • vehicle of bimatoprost formulation A solution
  • vehicle of bimatoprost solution 0.03 %
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth).
    Exclusion Criteria:
    * Damage to eyelid area (scarring) that may prevent growth of eyelashes * Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye) * Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening * Current eyelash implants of any kind * Eyelash tint or dye application within 2 months of baseline * Eyelash extensions application within 3 months of baseline * Use of eyelash growth products within 6 months of baseline * Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.

    Protocol Summary

    This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable
    Location
    Saint Petersburg, Russian Federation
    Status
    Not applicable
    Location
    Stockholm, Sweden
    Status
    Not applicable
    Location
    Norfolk, England, United Kingdom
    Status
    Not applicable